Department of Anesthesiology, and Dorothy M Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America.
PLoS One. 2012;7(8):e42500. doi: 10.1371/journal.pone.0042500. Epub 2012 Aug 24.
The pathways inducing the critical transition from compensated hypertrophy to cardiac dilation and failure remain poorly understood. The goal of our study is to determine the role of Rac-induced signaling in this transition process. Our previous results showed that Thyroxin (T4) treatment resulted in increased myocardial Rac expression in wild-type mice and a higher level of expression in Zea maize RacD (ZmRacD) transgenic mice. Our current results showed that T4 treatment induced physiologic cardiac hypertrophy in wild-type mice, as demonstrated by echocardiography and histopathology analyses. This was associated with significant increases in myocardial Rac-GTP, superoxide and ERK1/2 activities. Conversely, echocardiography and histopathology analyses showed that T4 treatment induced dilated cardiomyopathy along with compensatory cardiac hypertrophy in ZmRacD mice. These were linked with further increases in myocardial Rac-GTP, superoxide and ERK1/2 activities. Additionally, there were significant increases in caspase-8 expression and caspase-3 activity. However, there was a significant decrease in p38-MAPK activity. Interestingly, inhibition of myocardial Rac-GTP activity and superoxide generation with pravastatin and carvedilol, respectively, attenuated all functional, structural, and molecular changes associated with the T4-induced cardiomyopathy in ZmRacD mice except the compensatory cardiac hypertrophy. Taken together, T4-induced ZmRacD is a novel mouse model of dilated cardiomyopathy that shares many characteristics with the human disease phenotype. To our knowledge, this is the first study to show graded Rac-mediated O(2)·(-) results in cardiac phenotype shift in-vivo. Moreover, Rac-mediated O(2)·(-) generation, cardiomyocyte apoptosis, and myocardial fibrosis seem to play a pivotal role in the transition from cardiac hypertrophy to cardiac dilation and failure. Targeting Rac signaling could represent valuable therapeutic strategy not only in saving the failing myocardium but also to prevent this transition process.
导致从代偿性肥大到心脏扩张和衰竭的关键转变的途径仍知之甚少。我们的研究目标是确定 Rac 诱导的信号在这一转变过程中的作用。我们之前的结果表明,甲状腺素(T4)治疗导致野生型小鼠心肌 Rac 表达增加,并且在 Zea 玉米 RacD(ZmRacD)转基因小鼠中表达水平更高。我们目前的结果表明,T4 治疗诱导野生型小鼠产生生理性心肌肥大,超声心动图和组织病理学分析证实了这一点。这与心肌 Rac-GTP、超氧化物和 ERK1/2 活性的显著增加有关。相反,超声心动图和组织病理学分析表明,T4 治疗诱导 ZmRacD 小鼠扩张型心肌病伴代偿性心肌肥大。这与心肌 Rac-GTP、超氧化物和 ERK1/2 活性的进一步增加有关。此外,caspase-8 表达和 caspase-3 活性显著增加。然而,p38-MAPK 活性显著降低。有趣的是,用普伐他汀和卡维地洛分别抑制心肌 Rac-GTP 活性和超氧化物生成,可减轻 T4 诱导的 ZmRacD 小鼠所有与心肌病相关的功能、结构和分子变化,除了代偿性心肌肥大。总之,T4 诱导的 ZmRacD 是一种新型的扩张型心肌病小鼠模型,与人类疾病表型有许多共同特征。据我们所知,这是第一项表明 Rac 介导的 O(2)·(-) 在体内导致心脏表型转变的分级研究。此外,Rac 介导的 O(2)·(-)生成、心肌细胞凋亡和心肌纤维化似乎在从心肌肥大到心肌扩张和衰竭的转变中起着关键作用。靶向 Rac 信号可能不仅是挽救衰竭心肌的有价值的治疗策略,而且还可以预防这一转变过程。